Rafat Abonour

Rafat Abonour

Hematology Oncology

2111 Sole Mia Way 5th
Miami, FL 33181

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 73 publications

MRD in multiple myeloma: From an early endpoint for accelerated approval to MRD driven treatment and clinical management.

MRD in multiple myeloma: From an early endpoint for accelerated approval to MRD driven treatment and clinical management.

Journal: Seminars in hematology

Published: December 01, 2025

Bystander or perpetrator: Unravelling the significance and challenges of MGUS.

Bystander or perpetrator: Unravelling the significance and challenges of MGUS.

Journal: Blood reviews

Published: October 15, 2025

Bispecific T-cell engagers for relapsed/refractory multiple myeloma after solid organ transplantation: A case series.

Bispecific T-cell engagers for relapsed/refractory multiple myeloma after solid organ transplantation: A case series.

Journal: Journal of investigative medicine : the official publication of the American Federation for Clinical Research

Published: July 29, 2025

Diagnostic sequencing identifies high-risk markers and mechanisms of resistance to guide immunotherapy selection.

Diagnostic sequencing identifies high-risk markers and mechanisms of resistance to guide immunotherapy selection.

Journal: Blood advances

Published: July 09, 2025

Utilizing genomics to identify novel immunotherapeutic targets in multiple myeloma high-risk subgroups.

Utilizing genomics to identify novel immunotherapeutic targets in multiple myeloma high-risk subgroups.

Journal: Genome medicine

Published: February 03, 2025

Identification of the Distinct Immune Microenvironment Features Associated with Progression Following High-Dose Melphalan and Autologous Stem Cell Transplant in Multiple Myeloma.

Identification of the Distinct Immune Microenvironment Features Associated with Progression Following High-Dose Melphalan and Autologous Stem Cell Transplant in Multiple Myeloma.

Journal: Cancer immunology research

Published: January 14, 2025

The oligosaccharyltransferase complex is an essential component of multiple myeloma plasma cells.

The oligosaccharyltransferase complex is an essential component of multiple myeloma plasma cells.

Journal: Molecular therapy. Oncology

Published: September 24, 2024

Real-World Treatment Patterns and Clinical Outcomes in Patients With Multiple Myeloma Previously Treated With Lenalidomide and an Anti-CD38 Monoclonal Antibody.

Real-World Treatment Patterns and Clinical Outcomes in Patients With Multiple Myeloma Previously Treated With Lenalidomide and an Anti-CD38 Monoclonal Antibody.

Journal: Clinical lymphoma, myeloma & leukemia

Published: August 29, 2024

Characteristics and Treatment Patterns of Long-surviving Patients With Multiple Myeloma: Over 13 Years of Follow-up in the ConnectⓇ MM Registry.

Characteristics and Treatment Patterns of Long-surviving Patients With Multiple Myeloma: Over 13 Years of Follow-up in the ConnectⓇ MM Registry.

Journal: Clinical lymphoma, myeloma & leukemia

Published: July 08, 2024

Impact of lenalidomide-bortezomib-dexamethasone induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect® MM Registry.

Impact of lenalidomide-bortezomib-dexamethasone induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect® MM Registry.

Journal: Blood cancer journal

Published: June 13, 2024

High-dose chemotherapy and peripheral blood stem cell transplantation as salvage therapy in primary mediastinal nonseminomatous germ cell tumors: The Indiana University experience.

High-dose chemotherapy and peripheral blood stem cell transplantation as salvage therapy in primary mediastinal nonseminomatous germ cell tumors: The Indiana University experience.

Journal: Cancer

Published: January 23, 2024

The Effect of Age and Other Patient Characteristics on Outcomes Among Nontransplanted Patients Who Were Treated With First-Line Lenalidomide, Bortezomib, and Dexamethasone: Results From the ConnectⓇ MM Registry.

The Effect of Age and Other Patient Characteristics on Outcomes Among Nontransplanted Patients Who Were Treated With First-Line Lenalidomide, Bortezomib, and Dexamethasone: Results From the ConnectⓇ MM Registry.

Journal: Clinical lymphoma, myeloma & leukemia

Published: January 22, 2024

Showing 1-12 of 73

Last Updated: 09/26/2026